Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas

Anticancer Research

Volumn 19, Issue 1 B, 1999, Pages 869-873

  Edgren, Maliha ^a   Lennernäs, Bo ^b   Larsson, Anders ^a   Nilsson, Sten ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiogenesis; b FGF; Bladder; Prostate; Renal carcinomas; Survival; VEGF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; KIDNEY NEOPLASMS; LYMPHOKINES; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032949884     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Denekamp J: Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. 66: 181-196, 1993.
2. Folkman J: Clinical applications of research on angiogcncsis. N Eng J Med 333(26): 1757-1763, 1995.
3. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
4. Pili R, Guo Y, Chang J, et al: Altered angiogenesis underlying age-dependent changes in tumor growth. J Natl Cancer Inst 86: 1303-1314, 1994.
5. Gasparini G, Harris AL: Clinical importance of the determination of tumour angiogenesis in breast carcinoma: Much more than prognostic tool. J Clin Oncol 13: 765-782, 1995.
6. D'Amato RJ, Loughanan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91(9): 4082-4085, 1994.
7. Dirix LY, Vcrmeulen PB, Pawinski A, Prové A, Benoy I, De Pooter C, Martin M, Van Oosterom AT: Elevated levels of the angiogcnctic cytokinas basic fibroblast growth factor and vascular endothelium growth factor in sera of cancer patients. Br J Cancer 76(2): 238-43, 1997.
8. Vermeulen PB, Dirix LY, M.Martin M, Lemmens J, Van Oosterom AT:Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with Interferon Alfa-2b. J Natl Cancer Inst 89(17): 1316-1317, 1997.
9. Lawrence JA, Steeg PS: Mechanisms of tumor invasion and metastasis. World J Urology 14: 124-130, 1996.
10. Duensing S, Grosse J, Atzpodien J: Increased serum levels of basic fibroblast growth factor (b-FGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients. Anticancer Res 15(5B): 2331-3, 1995.
11. Vermeulen PB, Dirix LY, Martin M et al: Serum levels of b-FGF and VEGF in patients with metastatic solid tumours. Proceedings of ASCO 1996.
12. Weidner N, Folkman J: Tumoral vascularity as a prognostic factor in cancer. In: Important Advances in Oncology, (De Vita E, Hellman S and Ronserberg, eds).New York Lipponcott and Raven 1996, PP167-190.
13. Gohji K Fujimoto N, Komiyama T et al: Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 78(11): 2379-2387, 1996.
14. Nguyen M, Hiroyuki W, Budson AE, Richie JP, Folkman J: Elevated levels of the angiogenetic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 85: 24-25, 1993.
15. Joseph IBJK, Isaacs JT: Potention of the angiogenetic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res 57: 1054-1057, 1997.
16. Battegay EJ: Angiogenesis: mechanistic insights, neovascular diseases and therapeutic prospects. J Mol Med 73: 333-346, 1995.
17. Talbot DC, Brown PD: Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treament of cancer. Eur J Cancer 32A(14): 2528-2533, 1996.
18. Takahashi Y, Liu W, Yoneda J, Bucana CD, Ellis LM: The role of platelet derived endothelial cell growth factor (PD-ECGF) in the angiogenesis of human colon cancer. Proceedings of ASCO 1996.
19. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR: Increased expression of Vascular Permeability Factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Short communication. Am J Path 143(5): 1255-1262, 1993.
20. Nicol D, Su-ing HII, Walsh M, Teh B, Thompson L, Kennett C, Gotley D: Vascular endothelial growth factor expression in renal cell carcinoma. J Urol 157: 1482-1486, 1997.
21. Nakagawa M, Emoto A, Nomura Y: Expression of angiogenic factors in renal cell carcinomas (abstract).Proc Am Assoc Cancer Res 37: A378, 1996.
22. Takahashi A, Sasaki H, Kim SJ, Tobisu KI, Kakizoe T, Tsukamoto T: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54: 4233-4237, 1994.